



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Frovocimab

Cat. No.:	HY-P99626
CAS No.:	1643672-70-1
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 ^[1] .																
In Vitro	Frovocimab (LY 3015014) binds to intact but not truncated PCSK9. The selective binding of Frovocimab to intact PCSK9 is related to its binding epitope, the linear sequence of amino acids 160-181 of the catalytic domain of human PCSK9, which is absent in truncated PCSK9. Frovocimab inhibits PCSK9 binding to LDLR while permitting the normal proteolytic cleavage of the bound intact PCSK9. Additionally, upon cleavage, truncated inactive PCSK9 is released from Frovocimab ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
In Vivo	<p>Frovocimab (LY 3015014; 10 mg/kg; i.v; once) causes significant PCSK9 accumulation, its duration of LDL lowering is reduced, and its clearance (CL) from serum is accelerated in mice expressing a noncleavable variant of human PCSK9^[1]. Frovocimab (LY 3015014; 5 mg/kg; i.v; once) decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v; once</td> </tr> <tr> <td>Result:</td> <td>Caused significant PCSK9 accumulation.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus monkeys^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v; once</td> </tr> <tr> <td>Result:</td> <td>Decreased LDL cholesterol in monkeys.</td> </tr> </table>	Animal Model:	Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant ^[1]	Dosage:	10 mg/kg	Administration:	i.v; once	Result:	Caused significant PCSK9 accumulation.	Animal Model:	Cynomolgus monkeys ^[1]	Dosage:	5 mg/kg	Administration:	i.v; once	Result:	Decreased LDL cholesterol in monkeys.
Animal Model:	Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant ^[1]																
Dosage:	10 mg/kg																
Administration:	i.v; once																
Result:	Caused significant PCSK9 accumulation.																
Animal Model:	Cynomolgus monkeys ^[1]																
Dosage:	5 mg/kg																
Administration:	i.v; once																
Result:	Decreased LDL cholesterol in monkeys.																

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA